• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CDEX to Demonstrate Validation of Flu Vaccine and Flu Medications at The American Society of Health Systems Pharmacists (ASHP) MidYear Clinical Meeting, December 4-8

Posted on: Monday, 14 November 2005, 18:00 CST

CDEX Inc. (OTCBB:CEXI), developer of the ValiMed(TM) Medication Validation System and other innovative substance detection and verification systems, announces its participation in the 40th MidYear Clinical Meeting of the American Society of Health Systems Pharmacists (ASHP) December 4-8, 2005 in Las Vegas. At ASHP, CDEX will be demonstrating its ValiMed Medication Validation System, and demonstrating how CDEX technology can be utilized to validate authentic influenza vaccine and Tamiflu medication. Counterfeiting of influenza remedies and many other medications and vaccines is a growing problem.

In addition to anti-counterfeiting capabilities, CDEX's ValiMed System is being deployed by health-system pharmacists nationwide to verify compounded medications, correct dosages, and to validate narcotics returns.

CDEX will be located at ASHP Booth 1021 to demonstrate ValiMed's validation capabilities. Jim Griffin, COO, and Jerry Blair, VP of Business Operations, will be available for interviews.

In addition to demonstrations at the CDEX booth, the ValiMed solution will be highlighted at the following presentations at ASHP:

-- Presentation: Wednesday, 12/7/2005, 3:00 p.m. Use of Spectroscopy to Enhance Safety in IV Compounding, James G. Stevenson, Pharm.D., Director of Pharmacy Services, University of Michigan Health System, Ann Arbor

-- Poster: Monday, 12/5/2005, 2:00 p.m. Board 135, Improving medication safety: use of spectral medication validation in high risk intravenous medication (IV) compounding in a pediatric hospital pharmacy, Hanna Phan, Deborah Pasko, John F. Mitchell, Denise K. Glenn, Diane S. Shoemaker, James G. Stevenson

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of materials). CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.

Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects,""plans,""may,""anticipates,""believes,""should,""intends,""estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.

Source: Business Wire

More News in this Category